Class / Patent application number | Description | Number of patent applications / Date published |
514346000 | Chalcogen and acyclic nitrogen bonded directly to the same carbon | 31 |
20090215833 | Thermodynamically stable form of a tosylate salt - The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders. | 08-27-2009 |
20090312372 | CHEMICAL COMPOUNDS - Compounds of formula (I): | 12-17-2009 |
20110112151 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE - There is provided a compound of formula R | 05-12-2011 |
20110136877 | 2-PHENYL PHENOXYACETIC ACIDS USEFUL FOR TREATING INFLAMMATORY DISORDERS - The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I): | 06-09-2011 |
20110184028 | DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE - The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I inhibit HIV-integrase enzyme and are useful for preventing and treating of HIV infection and AIDS. | 07-28-2011 |
20120046322 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex - The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. | 02-23-2012 |
20120077851 | Urea Derivatives as Kinase Inhibitors - The present invention is directed to novel ureas, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R, R | 03-29-2012 |
20120095060 | METHODS AND COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAY INHIBITORS FOR TREATING PULMONARY FIBROSIS - Methods and compositions of inhibitors of MAPK kinases 1 and 2 (MEK1 and MEK2, or together, MEK1/2), such as ARRY142886, and their use in inhibiting MEK1/2 kinase activity in mammals for the treatment and/or reversal of the symptoms of pulmonary fibrosis. MEK1/2 inhibitors can selectively inhibit the MAPK/ERK pathway in vivo and prevent TGF-α mediated fibrosis. There are several distinct MAPK pathways that are important in the regulation of cell proliferation, differentiation, development, inflammation, survival, and migration. The Ras-Raf-MEK-ERK pathway (a key component of the MAPK pathway) via inhibition of MEK1/2 is an attractive strategy for therapeutic intervention in idiopathic pulmonary fibrosis, because inhibition of MEK1/2 has the potential to block inappropriate signal transduction leading to pulmonary fibrosis, regardless of the upstream position of the aberration causing it. | 04-19-2012 |
20120142741 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER - This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula I is as follows: | 06-07-2012 |
20120142742 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 06-07-2012 |
20120264789 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS - The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib. | 10-18-2012 |
20120289552 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY - This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes. | 11-15-2012 |
20120316204 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER - Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2α) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and/or a prodrug thereof which can be used to treat cancer. | 12-13-2012 |
20130005777 | SORAFENIB ETHYLSULFONATE SALT, PROCESS FOR PREPARATION AND USE - The present invention provides sorafenib ethane sulphonate, process for its preparation, pharmaceutical composition comprising sorafenib ethane sulphonate and its use for the treatment of cancer. Formula (III). | 01-03-2013 |
20130012548 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS - This invention relates to deuterated ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof. And the pharmaceutical compositions comprising the pharmaceutically acceptable carrier and the deuterium-substituted ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof are also provided. The deuterium-substituted diphenylurea can be used in treatment or prevention of cancer and other related diseases. | 01-10-2013 |
20130018075 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF - Disclosed are methods of treating hyperproliferative disorders, method of treating inflammatory disorders, and methods of inhibiting MEK activity in a mammal, comprising administering an effective amount of one or more compounds of the Formula V | 01-17-2013 |
20130102638 | METHODS AND COMPOSITIONS FOR CONTROLLING ALGAE - Described are preferred methods and compositions for controlling algae which involve the use of bleaching pyridinecarboxamide compounds. | 04-25-2013 |
20130116286 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION - The present invention is directed to methods of treating neurally mediated hypotension. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, that can be administered to a patient for the treatment of neurally mediated hypotension. | 05-09-2013 |
20130210865 | SORAFENIB DIMETHYL SULPHOXIDE SOLVATE - The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N | 08-15-2013 |
20130225641 | ANTICANCER COMPOUNDS AND PREPARATION METHODS THEREOF - Two new compounds with anticancer effects of N-[4-chloro-3-(trifluoromethyl)phenyl]-[4-(N-methyl-formamide)(4-pyridyloxy)phenyl]-thiourea and N-[4-chloro-3-(trifluoromethyl)phenyl]-[4-(N-methyl-formamide)(4-pyridylthio)phenyl]-thiourea, and salts thereof are disclosed. Preparation methods of the two new compounds and pharmaceutical compositions containing the new compounds are further disclosed. Experimental studies show that the two new compounds can effectively inhibit the activity of Raf and VEGFR protein kinase, widely inhibit growth of various types of human tumor cell lines and further induce apoptosis of tumor cells. Human tumor heterograft model investigation proves that the two new compounds are effective antineoplastic agents, and can sharply inhibit growth of human liver cancer cells, lung cancer cells and intestinal cancer cells in vivo. Furthermore, the anticancer effects of the compounds are much better than that of Sorafenib. | 08-29-2013 |
20130225642 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor. | 08-29-2013 |
20140045903 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex - The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. | 02-13-2014 |
20140088157 | ENDOPARASITE CONTROL AGENT - Provided are an endoparasite control agent comprising a carboxamide derivative represented by the general formula (I): | 03-27-2014 |
20140194476 | PYRIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELORIATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 07-10-2014 |
20140329866 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 11-06-2014 |
20150105432 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER - The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R | 04-16-2015 |
20150336895 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL - A fused heterocyclic compound represented by formula (1) has an excellent pest control effect. (In the formula, R | 11-26-2015 |
20160106694 | PHARMACEUTICAL COMPOSITIONS COMPRISING DROXIDOPA - The present invention provides combinations of droxidopa and one or more further pharmaceutically active compounds, said further compounds preferentially being selected from the group of COMT inhibiting compounds, cholinesterase inhibiting compounds, and monoamine oxidase inhibiting compounds. The invention further provides methods of treating conditions, such as orthostatic hypotension, comprising administering the combinations. | 04-21-2016 |
20160136143 | COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder. | 05-19-2016 |
20160166700 | METHOD FOR AMELIORATING LIVER FIBROSIS BY USING NANOPARTICLE CONTAINING TYROSINE KINASE INHIBITOR | 06-16-2016 |
20160376236 | SCALABLE PROCESS FOR THE PREPARATION OF SORAFENIB TOSYLATE ETHANOL SOLVATE AND SORAFENIB TOSYLATE FORM III - The present invention refers to an improved process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III. | 12-29-2016 |